Reported $456.3 million in cash resources as of December 31, 2023 , which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 Initiation of rolling biologics license application (BLA) filing with the FDA for zanidatamab as second-line
Continue Reading
